There have been major strides in the field of chronic lymphocytic leukemia (CLL) treatment over the last few years–with four new CLL medicines getting approval for use. All of these developments are incredible for a rare disease like CLL, but the new options have made it more difficult for doctors trying to decide which treatment to use.
There is no one size fits all approach for patients with CLL, according to Dr. Nicole Lamanna, a leukemia specialist at Columbia University Medical Center, but new oral chemotherapy drugs–like Ibrutinib, Idelalisib and Venetoclax–are really transforming the way this disease is treated. Even patients that have historically had a poor prognosis that did not respond to more traditional chemotherapy treatments are doing much better with these newer therapies.
There have been major strides when it comes to treating CLL in recent years. Since this is a disease that doesn’t always require treatment immediately, we asked top doctors to explain how they determine when and how to treat the disease.
For patients diagnosed with CLL, the go-to treatment option is usually some form of chemo-immunotherapy. But this is not an option for all patients.
Oral Medicine for Relapsed CLL: Venetoclax
Oral Medicine for CLL: Ibrutinib
Oral Medicine for Relapsed CLL